Hepatocyte-expressed HERC2 enhances type I interferon–mediated anti-HBV immune response by promoting K33 ubiquitination of TBK1
The Journal of Immunology · 2025
DOI: 10.1093/jimmun/vkaf095 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Zhuojun Zheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Research, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou…. Hauptthemen laut MEDLINE: Hepatocytes, Interferon Type I, Hepatitis B virus, Protein Serine-Threonine Kinases. Die Arbeit nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Provincial Key Laboratory of Immune Regulation and Immunotherapy, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Hepatitis B virus (HBV) infection remains a significant global health challenge, characterized by chronic liver inflammation and compromised antiviral immunity. The outcome of HBV infection and associated liver pathogenesis is influenced mainly by the host innate immune and inflammatory responses. Characterizing the mechanisms underlying these responses might provide new therapeutic strategies for HBV treatment. HECT domain and RCC1-like domain 2 (HERC2) belongs to the large HERC family of ubiquitin E3 ligases, which are implicated in tissue development and inflammation. We initially observed that hepatic tissues from chronic hepatitis B patients express lower levels of HERC2 compared with healthy donors. In this study, we identified HERC2 as a critical suppressor of HBV infection. Hepatocyte-specific HERC2-deficient mice exhibited increased susceptibility to HBV infection. Our findings demonstrate that HERC2 directly interacts with TBK1, a vital regulator of the innate immune response, mediating its K33 ubiquitination and activation. This HERC2-mediated activation of TBK1 triggers a signaling cascade that culminates in the activation of transcription factors IRF3 and IRF7, subsequently driving the production of type I interferons, crucial antiviral cytokines. The findings deepen our understanding of the molecular mechanisms underlying HBV pathogenesis and present potential avenues for developing targeted immunomodulatory therapies to combat HBV infection more effectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Research, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
- Institute of Molecular Immunology, School of Laboratory Medicine and Biotechnology, Guangdong Province Key Laboratory of Immune Regulation and Immunotherapy, Key Laboratory of Infectious Diseases Research in South China…
- State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong…
- Guangdong Province Key Laboratory of Proteomics, Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
- Guangdong Province Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, China.
ORCID-Profile: Jialiang Luo, Shuofeng Yuan, Daming Zuo, Qingyun Chen
Förderung
- National Natural Science Foundation of China
- Provincial Key Laboratory of Immune Regulation and Immunotherapy
- Natural Science Foundation of Guangdong Province
- Science and Technology Planning Project of Guangdong Province
Zitieren
APA
Zheng, Z., Cao, S., Liu, Y., Luo, J., Wang, H., Lu, X., Zhou, J., Yuan, S., Zuo, D., & Chen, Q. (2025). Hepatocyte-expressed HERC2 enhances type I interferon–mediated anti-HBV immune response by promoting K33 ubiquitination of TBK1. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf095
Vancouver
Zheng Z, Cao S, Liu Y, Luo J, Wang H, Lu X, et al. Hepatocyte-expressed HERC2 enhances type I interferon–mediated anti-HBV immune response by promoting K33 ubiquitination of TBK1. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf095
BibTeX
@article{Zheng2025,
author = {Zheng, Zhuojun and Cao, Sihang and Liu, Yunzhi and Luo, Jialiang and Wang, Hong and Lu, Xiao and Zhou, Jia and Yuan, Shuofeng and Zuo, Daming and Chen, Qingyun},
title = {Hepatocyte-expressed HERC2 enhances type I interferon–mediated anti-HBV immune response by promoting K33 ubiquitination of TBK1},
journal = {The Journal of Immunology},
year = {2025},
doi = {10.1093/jimmun/vkaf095}
}
EUVIMED